Who is sponsoring NCT06634407?

NCT06634407 is sponsored by Assiut University.

What drugs are being tested in NCT06634407?

Interventions in NCT06634407: transcatheter closure.

What condition does NCT06634407 study?

NCT06634407 studies Patent Ductus Arteriosus (PDA).

Is NCT06634407 still recruiting?

NCT06634407 is currently not yet recruiting. Last updated 22 October 2024.

Last reviewed 2024-10-22 · How we verify

NCT06634407

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcome of Transcatheter Closure of Patent Ductus Arteriosus in Pediatric Cardiology Unit in 3 Years Duration

Not yet recruiting NA Last updated 22 October 2024

What this trial tests

NA trial testing transcatheter closure in Patent Ductus Arteriosus (PDA) in 90 participants. Not yet recruiting.

Timeline

25 October 2024

Primary endpoint
1 September 2025

15 September 2025

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	25 October 2024
Primary completion	1 September 2025
Estimated completion	15 September 2025

Drugs / interventions tested

transcatheter closure

Conditions studied

Patent Ductus Arteriosus (PDA) — all drugs for Patent Ductus Arteriosus (PDA) →

Sponsor

Assiut University

Who can join

Adults 6 Months to 16, any sex, with Patent Ductus Arteriosus (PDA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Transcatheter Closure of Patent Ductus Arteriosus to evaluate the outcome of percutaneous transcatheter closure of patent ductus arteriosus in children

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06634407 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 22 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06634407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing